
Minjie Wei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2588338/publications.pdf Version: 2024-02-01



MINUE WEI

#	Article	IF	CITATIONS
1	A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis. Cell Death and Differentiation, 2022, 29, 1769-1789.	5.0	30
2	LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway. Journal of Experimental and Clinical Cancer Research, 2021, 40, 41.	3.5	30
3	lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration. Molecular Therapy - Nucleic Acids, 2021, 23, 536-551.	2.3	80
4	Integrated microenvironmentâ€associated genomic profiles identify LRRC15 mediating recurrent glioblastomaâ€associated macrophages infiltration. Journal of Cellular and Molecular Medicine, 2021, 25, 5534-5546.	1.6	7
5	NF-κB-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay. Oncogene, 2021, 40, 4919-4929.	2.6	15
6	N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer. Journal of Hematology and Oncology, 2021, 14, 188.	6.9	55
7	Immune-Related Long Non-coding RNA Constructs a Prognostic Signature of Ovarian Cancer. Biological Procedures Online, 2021, 23, 24.	1.4	5
8	Bioinformatic profiling identifies a platinumâ€resistant–related risk signature for ovarian cancer. Cancer Medicine, 2020, 9, 1242-1253.	1.3	8
9	LncRNA SPRY4â€IT1 regulates breast cancer cell stemness through competitively binding miRâ€6882â€3p with TCF7L2. Journal of Cellular and Molecular Medicine, 2020, 24, 772-784.	1.6	50
10	Development of an IFNγ responseâ€related signature for predicting the survival of cutaneous melanoma. Cancer Medicine, 2020, 9, 8186-8201.	1.3	17
11	Integrative Analysis of DNA Methylation and Gene Expression to Determine Specific Diagnostic Biomarkers and Prognostic Biomarkers of Breast Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 529386.	1.8	18
12	Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma. International Immunopharmacology, 2020, 89, 107162.	1.7	12
13	LNC942 promoting METTL14-mediated m6A methylation in breast cancer cell proliferation and progression. Oncogene, 2020, 39, 5358-5372.	2.6	131
14	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell, 2020, 38, 79-96.e11.	7.7	389
15	Expression signature of sixâ€snoRNA serves as novel nonâ€invasive biomarker for diagnosis and prognosis prediction of renal clear cell carcinoma. Journal of Cellular and Molecular Medicine, 2020, 24, 2215-2228.	1.6	32
16	LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miRâ€148aâ€3p/WNT1 pathway. Journal of Cellular and Molecular Medicine, 2020, 24, 6242-6252.	1.6	42
17	A fiveâ€mRNA signature associated with postâ€translational modifications can better predict recurrence and survival in cervical cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 6283-6297.	1.6	15
18	Long noncoding RNA ZFAS1 promoting small nucleolar RNA-mediated 2′-O-methylation via NOP58 recruitment in colorectal cancer. Molecular Cancer, 2020, 19, 95.	7.9	73

Minjie Wei

#	Article	IF	CITATIONS
19	Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 305.	3.5	107
20	Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death and Disease, 2019, 10, 666.	2.7	19
21	Hypoxiaâ€inducible factorâ€2α directly promotes <i><scp>BCRP</scp></i> expression and mediates the resistance of ovarian cancer stem cells to adriamycin. Molecular Oncology, 2019, 13, 403-421.	2.1	47
22	Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nature Cell Biology, 2018, 20, 285-295.	4.6	1,650
23	METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell Stem Cell, 2018, 22, 191-205.e9.	5.2	749
24	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell, 2018, 172, 90-105.e23.	13.5	794
25	High PITX1 expression in lung adenocarcinoma patients is associated with DNA methylation and poor prognosis. Pathology Research and Practice, 2018, 214, 2046-2053.	1.0	24
26	HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. Journal of Experimental and Clinical Cancer Research, 2018, 37, 256.	3.5	124
27	miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecologic Oncology, 2016, 141, 592-601.	0.6	51
28	MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). Journal of Experimental and Clinical Cancer Research, 2016, 35, 25.	3.5	82
29	The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. Clinical Science, 2015, 129, 809-822.	1.8	46